作者承认通过授予特蕾西J.羔羊儿童中心免疫与疫苗和美国国立卫生研究院新的创新奖（1DP2AI112242-01）的资金。作者还感谢纳塔利娅·P. Degtyareva为RAD1 S的慷慨捐助酵母。

1. UV诱变产生营养缺陷型酵母菌株<ol><li>生成生存曲线，以确定所需剂量的紫外线照射的<ol><li>根据标准方法26制备的YPD（酵母提取物蛋白胨葡萄糖）的媒体，在表1中列出的其它试剂和接种单个菌落到5-10毫升的YPD培养基。孵育在辊筒培养在30℃的CO / N至饱和至少8小时。 </li><li>通过稀释细胞1:10在水中的塑料比色杯中测定使用分光光度计O / N培养物的细胞浓度。稀释细胞在20ml无菌蒸馏水的10 7个细胞/ ml的浓度。 </li><li>倾稀释细胞进入无菌塑料培养皿，并与盖体取出，放置在板14厘米以下的UV灯泡。 </li><li>细胞暴露于串行5​​000μJ和10,000μJ剂量紫外线照射的，提取500微升细胞的每个增量，使得以下的细胞置身于0μJ，5000μJ10000μJ15000μJ20000μJ25000μJ30000μJ，4μJ，50000紫外线的照射μJ后进行采样。转移提取细胞样本无菌1.5毫升管，并在无菌水1:10的增量连续稀释。 </li><li>沉淀在在微量每个稀释离心细胞以16,000 xg离心1分钟。抽吸上清，重悬在无菌水中适当的电镀酵母细胞加入100μl体积。吸取全部体积悬浮细胞在含有YPD固体培养基平板，并使用无菌撒布在每个板对均匀分布的细胞。 </li><li>裹片边缘的封口膜，以防止媒体和盖板干燥铝箔，以防止光复活和紫外线诱发突变的修复。孵育板倒置，在30℃下2-4天以允许活酵母菌落（图1）的生长。 </li><li>算上numbe菌落R，可选择用钢笔的帮助下，划出菌落计数，手持电子计数器笔，或计数器站在放大倍率。积于UV照射的每个μJ总剂量接种的细胞的百分比，以产生用于照射酵母（图2）存活曲线。 注:单倍体酵母菌株可以预计需要较低剂量的照射相对于二倍体菌株紫外线到达相同百分比存活。酵母缺乏功能性DNA修复酶，如RAD1 S的应变酵母突变体，可以使用作为阳性对照，以指示紫外线照射的在非常低的剂量存在。 </li><li>确定紫外诱变的剂量通过参照建立在1.1.7生存曲线用于筛选。沿其中y等于50的存活曲线的点的x值是紫外线照射量在该酵母的50％存活。在这种低百分之存活筛选突变体可能会导致成功突变的菌株的较高产量，特别是对于二倍体酵母。的50％存活的剂量为WT S.布拉 ， 如图2中，是约18,000μJ。 注意:虽然这种高紫外线剂量增加突变的基因比感兴趣的营养缺陷型标记基因其他细胞通路的风险，该缺点必须针对需要以诱导突变的营养缺陷型标记基因的两个拷贝的平衡。对于单倍体菌株，其中仅一个基因拷贝必须进行突变，以更高的百分比存活筛选，例如在90％，降低的其他突变的风险，并仍允许足够产生营养缺陷型突变体。 </li></ol></li><li>紫外诱变和筛选营养缺陷型酵母菌株<ol><li>按照步骤1.1.1-1.1.3说明准备酵母。 </li><li>暴露酵母UV照射的对应于50％的存活率的剂量，如在1.1.8确定。对于WT S.酵母菌 ，这个剂量WA决心要为约18,000μJ（ 图2）。 </li><li>收集1毫升卷紫外线以16,000 xg离心在微量照射酵母和沉淀通过离心1分钟。吸去上清液和重悬的细胞在100μl无菌水中。 <ol><li>突变体的选择<ol><li>如果使用选择如与URA3 -营养缺陷型突变体，板照射酵母在含有5-氟乳清酸（5-FOA）的介质以选择缺少功能性的Ura3酶的细胞。 注:含有的Ura3的功能拷贝的任何酵母将5-FOA转换为毒素5-氟尿嘧啶，导致细胞死亡，并允许URA3的方便选择-即缺乏功能的Ura3 27菌落。类似的选择的方法是可能的LYS2和LYS5; TRP1;使用含有α氨基己二酸28媒体和MET2和MET15标记; 5-氟邻氨基苯甲酸29;和甲基汞30,31，分别。 </li><li>移液器100微升重新悬浮的细胞在含有5-FOA的基本培养基，并使用无菌吊具均匀涂覆板。包裹平板在封口膜孵育倒挂在30℃下2-4天以允许活酵母菌落的生长。 </li><li>通过restreaking到YPD，尿嘧啶出现在5-FOA平板的任何菌落表型- -确认URA3和5-FOA平板（图3）。用无菌牙签的尖端来收集单个菌落的一部分和整个新鲜的YPD，尿嘧啶轻轻拖动细胞-和5-FOA平板上。再次孵育包裹平板倒置，在30℃进行2-4天。 注:存活菌落将显示为凸起，大致呈圆形的生长而非存活细胞将仅显示为没有任何凸起的生长（图3）的不透明涂抹。 </li></ol></li><li>血肌酐突变体eening <ol><li>如果产生营养缺陷型突变的量选择方法都无法使用，制备紫外线的串行一点10稀释照射酵母细胞在无菌水中，并吸取稀释液到YPD培养基，用无菌吊具均匀涂覆板。 </li><li>裹在板封口膜，并培育倒挂在30℃2-4天。确定允许单个菌落生长，可以很容易地彼此区分，每板通常不超过约100个​​菌落其稀释。 </li><li>于本决定的稀释1.2.1-1.2.3和板细胞酵母说明样品重复紫外诱变。吸取稀释的酵母到YPD培养基中，使用无菌的吊具分发细胞，并孵育包裹平板倒置，在30℃进行2-4天。 </li><li>屏幕用于通过影印营养缺陷型到选择培养基缺乏感兴趣的代谢物。首先，安全无菌绒垫放在碟上的立场和反转用紫外线照射菌落板放置在绒布，标志着板的方向。 </li><li>接着，反转缺乏感兴趣的代谢物上的丝绒新鲜平板并轻轻地向下压，从绒转移细胞到板上。储存在4℃的原版。包装和孵化新盘倒挂在30℃2-4天。 </li><li>从YPD到选择性培养基通过重新裸奔殖民地替代影印，屏幕突变体。用无菌牙签的尖端来收集单个菌落的一部分，并轻轻地跨越新鲜的YPD板和缺乏兴趣代谢物的板拖动细胞。再次孵育包裹平板倒置，在30℃进行2-4天。 注意:必须小心选择单菌落和条纹出菌落多次确认真营养缺陷型细胞的同质群体。 </li></ol></li></ol></li><li>进一步证实照射细胞通过inoculat的表型ING单菌落到5-10毫升YPD双方，缺乏相应的代谢产物（如尿嘧啶-媒体的URA3 -突变体）的媒体。孵育在辊筒在30℃CO / N，以确认在​​YPD培养基中的细胞的生长，但不能在没有代谢物。 注意:虽然在固体培养基上生长模式应明确指出的酵母营养缺陷型状态，有可能对某些酵母耐受应力，并形成在固体培养基上小，缓慢生长的菌落，但尚未不能容忍在液体介质（未发表的观测值）相同的条件。接种到液体培养，因此应进行彻底检查照射紫外线的突变体的增长模式。 </li><li>为了证实营养缺陷突变体的长期存储，通过接种细胞准备甘油股票于10ml YPD，在30℃的辊筒O / N培养。离心沉淀细胞用于在2500 XG和吸媒体3分钟。悬浮细胞在50％的无菌过滤甘油，转移至冷冻管并储存于-80℃。 注:紫外线诱变酵母潜在地包含在比在感兴趣的营养缺陷型标记的其他多个基因突变。与验证使用营养缺陷型突变体在继续之前，这些菌株应进一步通过基因测序和pH值，胆汁酸胁迫性的评估，以及相关的益生菌菌株等特点进行了分析，如其他地方2描述。此外，使用PCR同源性或CRISPR的/ Cas9靶向更有选择性突变营养缺陷型标记应被视为替代紫外诱变4 - 6。 </li></ol></li></ol> 2.酵母转化<ol><li>酵母LiOAc转型<ol><li>接种单个酵母菌落入5-10毫升的YPD培养基中并在30℃的CO / N于辊筒孵育。 </li><li>以诱导对数期生长，提高质粒的摄取效率，德使用分光光度计termine细胞浓度测量在无菌水中1:10稀释的细胞在一个塑料杯中。稀O / N培养物至OD的0.16-0.2 600（约2×10 6 - 2.5×10 6个细胞/ ml）在50毫升新鲜温暖的YPD的孵育在轨道平台摇床设定为200转，直到培养细胞达到约1×10 7个细胞/ ml，通常为约4小时。 注意:转化效率可以为每质粒DNA微克成功转化的酵母细胞集落形成单位（CFU）的数目的函数来测量。每质粒DNA微克更多的转化菌落效率提高的结果。对数期生长过程中传代培养的酵母细胞和收集是增加转化效率12的一个因素。 </li><li>在2500 xg离心沉淀细胞离心3分钟。 </li><li>通过重悬佩尔吸出上清液并转移细胞到1.5 ml微量离心管等在1ml无菌水中。 </li><li>离心沉淀细胞在微量16000×g离心1分钟，吸出上清液，并再悬浮于1ml的TE / LiOAc液（Tris EDTA LiOAc）缓冲液洗涤细胞。 </li><li>重复离心和重悬细胞于TE / LiOAc缓冲至2×10 9细胞/ ml的浓度。 </li><li>制备转化混合物与每个如下:50微升的TE / LiOAc缓冲制备的酵母，5微升载体的DNA（10微克/微升）和1微升质粒DNA（1微克）的。质粒DNA的微克可滴定作为增加的DNA量可能会或可能不会导致转化效率32增加 注:对于缺少一个营养缺陷型标记的突变酵母菌株中，只有编码标记一个质粒可以每个样品进行改造。此外，利用编码易于检测的蛋白，如绿色荧光蛋白的质粒，将允许有效测定正确折叠和异源PR的表达通过转型后的酵母菌株otein。 </li><li>对于每个准备，加300微升PEG / LiOAc / TE和涡彻底的。完整的细胞与聚乙二醇的孵育为有效转化13是必不可少的。 </li><li>通过将离心管中以200rpm放置到一个轨道平台振荡器的烧杯中孵育在30℃下为在搅拌30分钟的准备。 </li><li>添加35微升DMSO中至每个反应和热休克细胞15分钟在42℃水浴中。虽然有冲突的DMSO中33的附加 ​​益处的报道，完整的酵母细胞的热休克已经显示出极大地提高转化效率12。 </li><li>通过经由离心造粒如2.1.5，抽吸或吸取掉上清，于1ml重悬浮无菌水洗涤细胞。吸管轻轻向上和向下，打破了细胞沉淀。 注:关键是要彻底去除上清因为媒体使用d。在产生的感受态细胞能抑制酵母菌的生长和集落形成。 </li><li>重复单元造粒如2.1.5，吸出上清液，并重新悬浮在100μl无菌水中的细胞。移液器全卷到选择性板使用无菌撒布均匀涂布板与转化酵母。 </li><li>裹涂布板的边缘在封口膜，以防止介质干燥，并培育倒挂在30℃下2天，以允许转化的酵母细胞的生长。成功，高效转化和酿酒酵母的营养缺陷型选择产生了大量的每转化制备菌落，虽然产率可以是用于其它菌株（图4）低得多。 </li><li>商店酵母板在短期内（一般为1-3周）倒过来，在4℃覆盖。作为长期储存在1.2.5中描述制备转化的酵母的甘油原液。 注:进一步的研究测试转化CFU的必要确定质粒稳定性和评估异源蛋白质的正确表达。质粒稳定性34，使用免疫印迹的透彻描述来检测从细胞样品17回收的变性蛋白，酶联免疫吸附试验（ELISA）来检测正确折叠三维蛋白16，并在酵母的研究中使用的GFP 35可用在别处。 图6显示了成功的GFP表达的转化的形象代表酵母相对于未转化的细胞。这种荧光蛋白的使用是有效地确定成功的异源蛋白的生产手段之一。 </li></ol></li><li>酵母的电穿孔<ol><li>接种单个酵母菌落入5-10毫升的YPD培养基中并在30℃的CO / N于辊筒孵育。 </li><li>使用分光光度计测量在无菌水中1:10稀释的细胞确定细胞浓度。迪琵琶O / N培养100毫升的新鲜温暖的YPD媒体的OD 600相当于约0.3。孵育在30℃下继代培养在轨道平台摇床设定为200rpm下，直到达到的OD 600约为1.6，通常是4-5小时。每次100ml亚文化将产生两个转化反应足够的条件细胞。 </li><li>在2500 xg离心沉淀细胞离心3分钟。吸出上清液并通过在50毫升冰冷的无菌水重悬洗涤细胞。通过制粒细胞，吸上清，在新鲜的50毫升冰水的冷无菌水重悬重复洗。 </li><li>再次沉淀细胞，并在50毫升冰冷的电穿孔缓冲液（1M山梨醇，1毫米氯化钙2）重悬。 </li><li>重复旋如2.2.3，吸去上清液，并悬浮细胞在20毫升的0.1M LiOAc / 10毫摩尔DTT。孵育细胞悬浮液上的辊筒在30℃下30分钟。在LiOAc和DTT细胞的预培养协同增加电穿孔36的效率。 </li><li>颗粒细胞作为2.2.3，上清，并在50毫升冰冷的电穿孔缓冲液中重悬洗。重复离心和重悬细胞的冰冷电穿孔缓冲液以1毫升的最终体积。 </li><li>制备在冰上:空调酵母细胞，无菌电试管，和质粒DNA。在1ml电穿孔缓冲液条件的细胞的最终再悬浮后，立即结合400μl的空调的酵母细胞用约1微克质粒DNA，并加入到冰冷的0.2微米的电穿孔杯中。的DNA量增加的使用可能会稍微提高转化效率11。在冰上孵育反应5分钟，然后用电穿孔集电穿孔至2.5千伏和25μF。 注:如2.1.7所述，缺少一个营养缺陷型标记的突变酵母菌株可以只用一个质粒编码每个采样突变标记物被转化。此外，使用编码易于检测的蛋白，如绿色荧光蛋白的质粒允许有效判定正确折叠和对变换随后的异源蛋白质的表达。 </li><li>传输电穿孔的细胞成8毫升1:YPD的1:1混合物:1M山梨醇和允许细胞在30℃下在辊筒孵育60分钟。 </li><li>丸细胞在2.2.3和在100μl1重悬:1 YPD:1M山梨醇。板全部体积在含1M山梨醇的选择性培养基，在封口膜包裹板的边缘，并孵育平板倒置，在30℃下2-5天以允许转化的酵母细胞的生长。 注:这是评价外源蛋白的正确表达，如2.1.14和2.2.7所述的试验转化酵母的关键。 </li></ol></li></ol> 3.转化酵母小鼠口服灌胃<ol><li>根据指南的实验室的管理和使用进行所有动物管理和处理程序imals和机构动物护理和使用委员会的批准。 </li><li>接种转化营养缺陷型酵母单菌落到5-10毫升的选择性培养基的制备O / N酵母培养物。在30℃下孵育培养物O / N为上辊筒的至少8小时，直到达到饱和。 注:质粒编码测试蛋白如GFP的使用将允许在管饲酵母易于蛋白表达的检测，如在4.7中描述。 </li><li>用于蛋白质表达的最大诱导和诱导对数期生长，从将O制备亚文化/ N培养物通过如2.1.2中所述稀释到OD 600当量为约0.16-0.2在50ml合适的介质中。 </li><li>确定传代培养细胞的浓度如在1.1.2和调整到10 9细胞/ ml。制备100μl的剂量为每只小鼠，每组几百微升额外体积，以提高准确度和缓解样品加载的。 </li><li>离心沉淀细胞在2500 XG为3分钟或在16,000 xg离心1分钟的离心。抽吸上清，重悬细胞，加入无菌水等体积和轻轻吹打上下。 </li><li>修正了一个合适的计灌胃针（15-20摹老鼠22克）到1毫升无菌注射器和负载酵母样品时，应确保消除任何气泡，并设置柱塞100微升增量。负载无菌水灌胃对照组小鼠的额外的注射器，并检查是否有任何污染酵母的存在。 </li><li>拾取到使用非优势手来管饲小鼠，用食指和拇指紧紧抓在脖子上（图6A）的皮肤。掖下的小手指的尾部，以防止下主体的运动。可以肯定的把手是安全的，并从以防止管饲期间内部组织损伤移动其头部禁止鼠标。 注:估计握住针对鼠标使得灌胃针多远应插入灯泡是即使在胸骨的剑突。插入这个长度针通常将允许灌胃针球进入胃。 </li><li>使用优势手，轻轻钓鱼沿着嘴和咽喉的背面的屋顶针，稍保持到中心的左边插入灌胃针入小鼠食道。等待鼠标吞针的灯泡和允许针稍微进一步下降到3.7（图6B）所估计的点。如果灌胃针插入过程中或如果鼠标在任何时候开始喘气感觉到任何阻力，轻轻取出针，并再次试图找到食道。 </li><li>鼠标已经吞噬了灌胃针的球后，轻踏注射器活塞管理酵母100微升（10 8 CFU）直接进入小鼠胃。 注:尽管小鼠不能管理18,19后呕吐任何灌胃解决方案</SUP&gt;，它有可能为管饲21,37期间发生回流。正确插入的管饲针，以及调节溶液的体积和粘度，可以有助于限制回流并确保准确的剂量。 </li><li>小心地从小鼠胃和食道灌胃针和鼠标返回到笼子里。检查小鼠呼吸，并且管饲后正常转动，以确保灌胃针被正确地在整个过程，并且没有溶液吸插入。 </li></ol> 4.鼠淋巴集结收获和隔离活酵母菌落<ol><li>在适当的时间点后灌服，一般是4小时，使用IACUC牺牲小鼠认可的方法。检查下一个脚趾捏缺乏响应能力，并使用一个辅助措施，如颈椎脱臼牺牲鼠标。另外的时间点，也可以进行测试，因为大量的研究已经表明，效率和启动定时采取跨越上皮颗粒依赖38,39。 </li><li>躺在充分暴露腹部鼠标和通过用70％乙醇喷雾消毒腹部区域。做一个横切口通过皮毛和皮肤用剪刀，小心不要破坏任何内部组织。手动撬切口打开进一步揭露腹膜，薄浆膜衬里覆盖腹部器官。轻轻提起腹膜，并作一横切口，显露肠子。 </li><li>小心使用钝钳逗小肠从肠系膜动脉，脂肪和其他组织的路程。从胃暴露小肠，在小鼠腹部的左上象限，盲肠，大袋肠组织中的大肠的开始。 </li><li>通过寻找1-3毫米沿着小肠不透明组织的大致圆形的补丁（图7）隔离淋巴集结。采用弧形夹层SCIS感器，切掉淋巴集结的圆顶，留下的利润，以确保没有周围的固有层被收集。 注:大多数小鼠有4-8轻松可见淋巴集结之间。与直接头顶照明的区域执行的程序将增加与淋巴集结可以可视化的难易程度。 </li><li>收集解剖淋巴集结在完整Iscove氏改性Dulbecco氏培养基（IMDM）。 注:这是为了防止酵母板胃肠道细菌污染使用无菌技术，包括抗生素在收集媒体的关键。 </li><li>通过一个40微米的细胞滤网过滤淋巴集结，以消除收集媒体。洗涤Peyer氏用新鲜的完全的IMDM修补过的50ml管中，并使用柱塞从1ml注射器轻轻打散淋巴集结。颗粒离心细胞紧张转速为1,800 rpm 7分钟。吸上清，重悬细胞大约100微升的最终体积。 </li><li>应用应变细胞上选择性酵母培养基，并使用板吊具均匀分布的细胞。裹片边缘在封口膜孵育平板倒置，在30℃下进行2天，以便用于从鼠淋巴集结中回收任何可行的酵母的生长。 注意:从淋巴集结"补丁酵母的恢复后需要进一步的研究，以确认该菌株能够提供正确折叠的异源蛋白质，以这些免疫组织。如在2.1.14中描述，这样的方法可包括免疫印迹，ELISA或荧光显微镜检测荧光蛋白如GFP 2,40。 </li></ol>

<ol><li>Edwards-Ingram, L., Gitsham, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genotypic+and+physiological+characterization+of+Saccharomyces+boulardii%2C+the+probiotic+strain+of+Saccharomyces+cerevisiae%5BTitle%5D)+AND+%22Applied+and+environmental+microbiology%22%5BJournal%5D)">Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.</a> Applied and environmental microbiology. 73 (8), 2458-2467 (2007).</li>
<li>Hudson, L. E., Fasken, M. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Functional+Heterologous+Protein+Expression+by+Genetically+Engineered+Probiotic+Yeast+Saccharomyces+boulardii%5BTitle%5D)+AND+%22PloS+one%22%5BJournal%5D)">Functional Heterologous Protein Expression by Genetically Engineered Probiotic Yeast Saccharomyces boulardii.</a> PloS one. 9 (11), 1-12 (2014).</li>
<li><a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=%22Methods+in+Enzymology%2C+Volume+149%3A+Guide+to+Yeast+Genetics+and+Molecular+Biology%22">Methods in Enzymology, Volume 149: Guide to Yeast Genetics and Molecular Biology</a>. Guthrie, C., Fink, G. R. , (1991).</li>
<li>DiCarlo, J. E., Norville, J. E., Mali, P., Rios, X., Aach, J., Church, G. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genome+engineering+in+Saccharomyces+cerevisiae+using+CRISPR-Cas+systems%5BTitle%5D)+AND+%22Nucleic+acids+research%22%5BJournal%5D)">Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems.</a> Nucleic acids research. 41 (7), 4336-4343 (2013).</li>
<li>Sander, J. D., Joung, J. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cas+systems+for+editing%2C+regulating+and+targeting+genomes%5BTitle%5D)+AND+%22Nature+biotechnology%22%5BJournal%5D)">CRISPR-Cas systems for editing, regulating and targeting genomes.</a> Nature biotechnology. 32 (4), 347-355 (2014).</li>
<li>Lorenz, M. C., Muir, R. S., Lim, E., McElver, J., Weber, S. C., Heitman, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gene+disruption+with+PCR+products+in+Saccharomyces+cerevisiae%5BTitle%5D)+AND+%22Gene%22%5BJournal%5D)">Gene disruption with PCR products in Saccharomyces cerevisiae.</a> Gene. 158, 113-117 (1995).</li>
<li>Hamedi, H., Misaghi, A., Modarressi, M. H., Salehi, T. Z., Khorasanizadeh, D., Khalaj, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+a+Uracil+Auxotroph+Strain+of+the+Probiotic+Yeast+Saccharomyces+boulardii+as+a+Host+for+the+Recombinant+Protein+Production%5BTitle%5D)+AND+%22Avicenna+Journal+of+Medical+Biotechnology%22%5BJournal%5D)">Generation of a Uracil Auxotroph Strain of the Probiotic Yeast Saccharomyces boulardii as a Host for the Recombinant Protein Production.</a> Avicenna Journal of Medical Biotechnology. 5 (1), 29-34 (2013).</li>
<li>Hinnen, A., Hicks, J. B., Fink, G. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transformation+of+yeast%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Transformation of yeast.</a> Proceedings of the National Academy of Sciences of the United States of America. 75 (4), 1929-1933 (1978).</li>
<li>Hashimoto, H., Morikawa, H., Yamada, K., Kimura, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+novel+method+for+transformation+of+intact+yeast+cells+by+electroinjection+of+plasmid+DNA%5BTitle%5D)+AND+%22Appl+Microbiol+Biotechnol%22%5BJournal%5D)">A novel method for transformation of intact yeast cells by electroinjection of plasmid DNA.</a> Appl Microbiol Biotechnol. 21, 336-339 (1985).</li>
<li>Becker, D., Guarente, L. High-efficiency transformation of yeast by electroporation. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aBecker%2C+D+%22Methods+in+Enzymology%2C+Volume+149%3A+Guide+to+Yeast+Genetics+and+Molecular+Biology%22">Methods in Enzymology, Volume 149: Guide to Yeast Genetics and Molecular Biology</a>. , 182-187 (1991).</li>
<li>Benatuil, L., Perez, J. M., Belk, J., Hsieh, C. -M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+improved+yeast+transformation+method+for+the+generation+of+very+large+human+antibody+libraries%5BTitle%5D)+AND+%22Protein+engineering%2C+design+%26+selection+%3A+PEDS%22%5BJournal%5D)">An improved yeast transformation method for the generation of very large human antibody libraries.</a> Protein engineering, design & selection : PEDS. 23 (4), 155-159 (2010).</li>
<li>Ito, H., Fukuda, Y., Murata, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transformation+of+intact+yeast+cells+treated+with+alkali+cations%5BTitle%5D)+AND+%22Journal+of+Bacteriology%22%5BJournal%5D)">Transformation of intact yeast cells treated with alkali cations.</a> Journal of Bacteriology. 153 (1), 166-168 (1983).</li>
<li>Kawai, S., Hashimoto, W., Murata, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transformation+of+Saccharomyces+cerevisiae+and+other+fungi%3A+methods+and+possible+underlying+mechanism%5BTitle%5D)+AND+%22Bioengineered+bugs%22%5BJournal%5D)">Transformation of Saccharomyces cerevisiae and other fungi: methods and possible underlying mechanism.</a> Bioengineered bugs. 1 (6), 395-403 (2010).</li>
<li>Zheng, H. Z., Liu, H. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Yeast+transformation+process+studied+by+fluorescence+labeling+technique%5BTitle%5D)+AND+%22Bioconjugate+Chemistry%22%5BJournal%5D)">Yeast transformation process studied by fluorescence labeling technique.</a> Bioconjugate Chemistry. 16, 250-254 (2005).</li>
<li>Gietz, R. D., Woods, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genetic+transformation+of+yeast%5BTitle%5D)+AND+%22BioTechniques%22%5BJournal%5D)">Genetic transformation of yeast.</a> BioTechniques. 30 (4), 816-831 (2001).</li>
<li>JoVE Science Education Database. The ELISA Method. . <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=%22Basic+Methods+in+Cellular+and+Molecular+Biology%22">Basic Methods in Cellular and Molecular Biology</a>. , (2015).</li>
<li>Gallagher, S., Chakavarti, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunoblot+analysis%5BTitle%5D)+AND+%22Journal+of+visualized+experiments+%3A+JoVE%22%5BJournal%5D)">Immunoblot analysis.</a> Journal of visualized experiments : JoVE. (16), (2008).</li>
<li>Horn, C. C., Kimball, B. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Why+Can%27t+Rodents+Vomit%3F+A+Comparative+Behavioral%2C+Anatomical%2C+and+Physiological+Study%5BTitle%5D)+AND+%22+PLoS+ONE%22%5BJournal%5D)">Why Can't Rodents Vomit? A Comparative Behavioral, Anatomical, and Physiological Study.</a> PLoS ONE. 8 (4), (2013).</li>
<li>Hoggatt, A. F., Hoggatt, J., Honerlaw, M., Pelus, L. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+spoonful+of+sugar+helps+the+medicine+go+down%3A+a+novel+technique+to+improve+oral+gavage+in+mice%5BTitle%5D)+AND+%22Journal+of+the+American+Association+for+Laboratory+Animal+Science+%3A+JAALAS%22%5BJournal%5D)">A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice.</a> Journal of the American Association for Laboratory Animal Science : JAALAS. 49 (3), 329-334 (2010).</li>
<li>Johnson, M., Shayne, C. G., Kemper, C. J. The rat. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aJohnson%2C+M+%22Animal+Models+in+Toxicology%22">Animal Models in Toxicology</a>. , 50-193 (2006).</li>
<li>Brown, A. P., Dinger, N., Levine, B. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Stress+produced+by+gavage+administration+in+the+rat%5BTitle%5D)+AND+%22Contemporary+topics+in+laboratory+animal+science+%2F+American+Association+for+Laboratory+Animal+Science%22%5BJournal%5D)">Stress produced by gavage administration in the rat.</a> Contemporary topics in laboratory animal science / American Association for Laboratory Animal Science. 39, 17-21 (2000).</li>
<li>Jacoby, R., Fox, J., Davisson, M. Biology and diseases of mice. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aJacoby%2C+R+%22Laboratory+animal+medicine%22">Laboratory animal medicine</a>. , 35-133 (2002).</li>
<li>Schulz, O., Pabst, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antigen+sampling+in+the+small+intestine%5BTitle%5D)+AND+%22Trends+in+immunology%22%5BJournal%5D)">Antigen sampling in the small intestine.</a> Trends in immunology. 34 (4), 155-161 (2013).</li>
<li>McDole, J. R., Wheeler, L. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Goblet+cells+deliver+luminal+antigen+to+CD103%2B+dendritic+cells+in+the+small+intestine%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine.</a> Nature. 483 (7389), 345-349 (2012).</li>
<li>Farache, J., Koren, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Luminal+bacteria+recruit+CD103%2B+dendritic+cells+into+the+intestinal+epithelium+to+sample+bacterial+antigens+for+presentation%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation.</a> Immunity. 38 (3), 581-595 (2013).</li>
<li>Burke, D., Dawson, D., Stearns, T. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aBurke%2C+D+%22Methods+in+yeast+genetics%3A+a+Cold+Spring+Harbor+Laboratory+course+manual%22">Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual</a>. , Cold Spring Harbor Lab Press. (2000).</li>
<li>Boeke, J. D., LaCroute, F., Fink, G. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+positive+selection+for+mutants+lacking+orotidine-5%27-phosphate+decarboxylase+activity+in+yeast%3A+5-fluoro-orotic+acid+resistance%5BTitle%5D)+AND+%22Molecular+%26+general+genetics+%3A+MGG%22%5BJournal%5D)">A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance.</a> Molecular & general genetics : MGG. 197 (2), 345-346 (1984).</li>
<li>Chattoo, B. B., Sherman, F., Azubalis, D. A., Fjellstedt, T. A., Mehnert, D., Ogur, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Selection+of+lys2+mutants+of+the+yeast+Saccharomyces+cerevisiae+by+the+utilization+of+alpha-aminoadipate%5BTitle%5D)+AND+%22Genetics%22%5BJournal%5D)">Selection of lys2 mutants of the yeast Saccharomyces cerevisiae by the utilization of alpha-aminoadipate.</a> Genetics. 93, 51-65 (1979).</li>
<li>Toyn, J. H., Gunyuzlu, P. L., White, W. H., La Thompson,, Hollis, G. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+counterselection+for+the+tryptophan+pathway+in+yeast%3A+5-fluoroanthranilic+acid+resistance%5BTitle%5D)+AND+%22Yeast%22%5BJournal%5D)">A counterselection for the tryptophan pathway in yeast: 5-fluoroanthranilic acid resistance.</a> Yeast. 16 (6), Chichester, England. 553-560 (2000).</li>
<li>Singh, A., Sherman, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genetic+and+physiological+characterization+of+met15+mutants+of+Saccharomyces+cerevisiae%3A+a+selective+system+for+forward+and+reverse+mutations%5BTitle%5D)+AND+%22Genetics%22%5BJournal%5D)">Genetic and physiological characterization of met15 mutants of Saccharomyces cerevisiae: a selective system for forward and reverse mutations.</a> Genetics. 81, 75-97 (1975).</li>
<li>Singh, A., Sherman, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Characteristics+and+relationships+of+mercury+resistant+mutants+and+methionine+auxotrophs+of+yeast%5BTitle%5D)+AND+%22Journal+of+Bacteriology%22%5BJournal%5D)">Characteristics and relationships of mercury resistant mutants and methionine auxotrophs of yeast.</a> Journal of Bacteriology. 118 (3), 911-918 (1974).</li>
<li>McCoy, S. L., Hausman, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantification+of+DNA+binding+to+cell-surfaces+by+flow+cytometry%5BTitle%5D)+AND+%22Journal+of+Immunological+Methods%22%5BJournal%5D)">Quantification of DNA binding to cell-surfaces by flow cytometry.</a> Journal of Immunological Methods. 241, 141-146 (2000).</li>
<li>Gietz, R. D., Schiestl, R. H., Willems, A. R., Woods, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Studies+on+the+transformation+of+intact+yeast+cells+by+the+LiAc%2FSS-DNA%2FPEG+procedure%5BTitle%5D)+AND+%22Yeast%22%5BJournal%5D)">Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure.</a> Yeast. 11, 355-360 (1995).</li>
<li>Zhang, Z., Chisti, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Plasmid+stability+in+recombinant+saccharomyces+cerevisiae%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Plasmid stability in recombinant saccharomyces cerevisiae.</a> Science. 14 (4), 401-435 (1996).</li>
<li>Lorang, J. M., Tuori, R. P., Martinez, J. P., Sawyer, T. L., Redman, R. S., Rollins, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Green+Fluorescent+Protein+Is+Lighting+Up+Fungal+Biology%5BTitle%5D)+AND+%22Applied+and+Environmental+Microbiology%22%5BJournal%5D)">Green Fluorescent Protein Is Lighting Up Fungal Biology.</a> Applied and Environmental Microbiology. 67 (5), 1987-1994 (2001).</li>
<li>Thompson, J. R., Register, E., Curotto, J., Kurtz, M., Kelly, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+improved+protocol+for+the+preparation+of+yeast+cells+for+transformation+by+electroporation%5BTitle%5D)+AND+%22Yeast%22%5BJournal%5D)">An improved protocol for the preparation of yeast cells for transformation by electroporation.</a> Yeast. 14, 565-571 (1998).</li>
<li>Damsch, S., Eichenbaum, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gavage-related+reflux+in+rats%3A+identification%2C+pathogenesis%2C+and+toxicological+implications+%28review%29%5BTitle%5D)+AND+%22Toxicologic+pathology%22%5BJournal%5D)">Gavage-related reflux in rats: identification, pathogenesis, and toxicological implications (review).</a> Toxicologic pathology. 39, 348-360 (2011).</li>
<li>Desai, M., Labhasetwar, V., Amidon, G., Levy, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gastrointestinal+uptake+of+biodegradable+nanoparticles%3A+effect+of+particle+size%5BTitle%5D)+AND+%22Pharma%22%5BJournal%5D)">Gastrointestinal uptake of biodegradable nanoparticles: effect of particle size.</a> Pharma. 13 (12), (1994).</li>
<li>Shakweh, M., Ponchel, G., Fattal, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Particle+uptake+by+Peyer%27s+patches%3A+a+pathway+for+drug+and+vaccine+delivery%5BTitle%5D)+AND+%22Expert+opinion+on+drug+delivery%22%5BJournal%5D)">Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery.</a> Expert opinion on drug delivery. 1 (1), (2004).</li>
<li>Szymanski, E. P., Kerscher, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Budding+yeast+protein+extraction+and+purification+for+the+study+of+function%2C+interactions%2C+and+post-translational+modifications%5BTitle%5D)+AND+%22Journal+of+visualized+experiments+%3A+JoVE%22%5BJournal%5D)">Budding yeast protein extraction and purification for the study of function, interactions, and post-translational modifications.</a> Journal of visualized experiments : JoVE. (80), e50921(2013).</li>
<li>Hashimoto, S., Ogura, M., Aritomi, K., Hoshida, H., Nishizawa, Y., Akada, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation+of+Auxotrophic+Mutants+of+Diploid+Industrial+Yeast+Strains+after+UV+Mutagenesis%5BTitle%5D)+AND+%22Applied+and+environmental+microbiology%22%5BJournal%5D)">Isolation of Auxotrophic Mutants of Diploid Industrial Yeast Strains after UV Mutagenesis.</a> Applied and environmental microbiology. 71 (1), 312-319 (2005).</li>
</ol>

作者什么都没有透露。

一起，这些协议本文描述所必需的开发和营养缺陷型益生菌酵母菌株的测试用于递送外源治疗性蛋白质的于肠的基本步骤。这种操纵和重组益生菌酵母的测试需要的技术和资源，与任何个人的实验室目前可能不熟悉。因此，尽管先前的许多研究已经说明上述协议多次酵母和小鼠品系，这些方法都没有作者的知识进行了详细，统一的形式提交。此外，本手稿特别强调适应当前标准化协议为益生菌酵?...

益生菌微生物是有效和经济地提供异源蛋白对胃肠道一个有趣的电位的装置。这些微生物能够通过胃肠道存活通路还没有殖它1，使控制剂量和限制性的药物表示曝光的。此外，为了容易工程师这些生物体产生大规模的异源蛋白质的能力使它们的经济替代合成递送颗粒。然而，这样的方法的开发，作为使用益生菌酵母布拉酵母菌 2的营养缺陷型菌株最近证明，需要的实验室技术在给定研究中传统上不结合，从酵母和分子生物学到动物处理技术和免疫学方法的知识。因此，尽管本文所描述的各个过程本身并不新颖实验室协议，本手稿的目标是提出一种统一介绍所需益生菌酵母的实验测试作为药物递送载体的鼠胃肠道的技术。提供是为必要的协议汇编:1）代的酵母的营养缺陷型突变株，可以很容易进行遗传操纵的; 2）酵母培养的改造，表达外源蛋白; 3）重组酵母经口服灌胃肠道的管理;和4）从它们的异源蛋白质表达的鼠肠和评估可行重组益生菌酵母的回收​​。 首先，虽然用于酵母物种的操作存在许多阳性和阴性选择方法，阴性选择如通过利用营养缺陷型标记的增大的效率和缓解与酵母可转化和选择。使用抗生素转化的积极选择，在合作ntrast，显著增加酵母操纵的成本。此外，酵母在含有抗生素的固体培养基的选择可允许相对于合成滴出固体介质（未发表的观测值）的营养缺陷型酵母的选择未转化的背景菌落增加的生长。营养缺陷型酵母是缺乏酶的必需氨基酸或尿嘧啶的合成关键菌株。如果补充丢失的代谢产物或代谢基因，从而使消极的选择，当酵母接种到合成辍学媒体缺乏必要的代谢产物如酵母只能生长。许多常用的酿酒酵母的实验室菌株中实际上已经营养缺陷型突变体3。工业，临床和益生菌酵母菌株，但是，通常是原养与合成所需的所有营养物质的能力。为了使这样的酵母更高效的基因操作，营养缺陷型的基因可以被选择性地定位产生能够无抗生素选择菌株。 6 -营养缺陷型的标记基因特异性靶向可通过PCR介导的基因破坏依靠同源重组或最近通过CRISPR / Cas9目标4来实现。可替代地，紫外诱变可以快速生成，即使在酵母菌株为哪些变换与多个质粒在技术上是困难7营养缺陷型突变体。虽然PCR定位和CRISPR / Cas9已经被广泛地描述在其他地方，部分提出这个手稿之一是描述紫外诱变的方法来创建营养缺陷型菌株，将允许阴性选择，而不是酵母转化的积极的抗生素选择一个详细的协议。 在使用为异源蛋白质的口服递送这样的营养缺陷型菌株的下一个必要的步骤是酵母转化用质粒DNA。由于赞成票的第一个成功转型在1978年8报道了酿酒酵母牛逼的球状体，大量的修改进行了表征，以提高效率和易用性与酵母菌种可遗传修饰。利用电对DNA的成功转型为S.酵母最早是在1985年9节 ，至今已通过加入1M山梨醇培养渗透到细胞支持10提高。电效率此外，已显示依赖于酵母种和菌株，细胞数和生长的阶段，电体积，电场强度，和特定的缓冲区11。醋酸锂（LiOAc）变换，最初由Ito等人12所述，是最常用的变换协议之间，因为它不需要特殊的设备。附加分析表明，LiOAc酵母转化效率时，细胞在数中期收集大大增加生长并热在聚乙二醇（PEG）和DNA的存在下，在42℃12震惊。用PEG整个完整的酵母的培养是高效转化必需的，有可能通过提高DNA与细胞膜的附着以及通过在膜13等效果。锂本身也增加了完整细胞14的渗透性。尽管大多数实验室S.酵母菌株可以很容易地使用LiOAc变换3被转化，其它酵母物种可更有效地使用替代的协议变换。 巴斯德毕赤酵母 ，例如，是通过电穿孔，而不是LiOAc变换13最有效地转化，这是至关重要的，因此，要测试多个改造和方法，试图在基因修改未鉴定的酵母菌株，优化培养时间和试剂浓度。这份手稿从而描述了两种LiOAc TRansformation和电穿孔作为营养缺陷型突变体和野生型S的转化技术布拉 。感兴趣的读者可以直接用于酵母转化，替代协议和行动13,15的可能机制进一步讨论演变的深入描述最近的评论。用质粒编码易于检测的蛋白质的酵母的转化是为了确保正确的表达和异源蛋白质的功能下游测试进一步必要的。无数的不同蛋白质可以根据治疗研究的最终目的和通过免疫印迹，ELISA和其它技术可用于蛋白质检测的抗体来选择。对这些技术的协议已被彻底别处16,17描述，并且可用于通过比较标准曲线，以确定从转化的酵母异源蛋白质的生产水平。为目的的示范的，并显示出成功地生产在酵母生物学一个很常用的蛋白质，这手稿呈现质粒编码绿色荧光蛋白（GFP），其允许使用荧光显微镜后续检测转变。 到生产表达异源蛋白质是适当管理和胃肠组织内的这些微生物的检测，如在第三和第四部分中描述的益生菌微生物的同样重要。通过口服管饲法重组酵母的施用允许递送的酵母的控制量直接进入胃，从中C57BL / 6小鼠是自然不能呕吐18。然而，不当处理动物灌胃，并可能导致食管损伤，穿孔，胃穿孔，气管管理和吸入性肺炎19,20。可怜的技术和缺乏经验可以进一步提高小鼠的免疫反应和实验地区环境部门一道变异LTS，已经口服管饲法21,22归因于动物的压力。在适当的技术实践可因此不仅衰减动物的不适，但也可以增加的实验结果的精度。这份手稿介绍并演示了动物处理和口服灌胃的掌握剂量重组酵母的管​​理。 最后，这是至关重要的，通过分析淋巴组织用于酵母和异源蛋白质的存在下，以确认重组酵母的成功递送。可以最容易地且可预测地检测为酵母的存在下消化道免疫组织是淋巴集结。淋巴集结沿小肠二级淋巴器官是粘膜免疫应答的诱导23关键点。从内腔抗原通过微皱transcellularly转印在上皮（M）的细胞和被释放到淋巴集结，从而暴露括D抗原呈递细胞肠肠腔内容物。虽然在整个肠上皮粒子的摄取也可以由杯状细胞来实现，这些细胞已被证明仅占用颗粒小于0.02微米的直径24。跨上树突从CD103 +树突状细胞（DC）也采取了从肠道小颗粒管腔25延伸;然而，目前还没有报告表明CD103 +的DC占用比细菌大颗粒。因此，完好的益生菌酵母，3-6微米直径之间的平均大小，最有可能由M细胞吸收并转移到淋巴集结。这里描述的是用于收集和淋巴集结为可行的重组酵母的筛选的协议，虽然这过程也可以容易地适应用于评估益生菌摄取。 综上所述，评估重组益生菌酵母的交付rapeutic蛋白质在肠道需要实验室技术跨越分子生物学动物处理和免疫能力。 1这里提出是协议），它可以很容易地无抗生素负选择的生成和营养缺陷型酵母菌株的筛选，2）替代协议来转化酵母，并启用异源蛋白质的表达，3）的适当的动物处理方法和用于口服管饲法示范胃内递送重组酵母的，4）协议淋巴集结解剖和筛选可行的重组酵母和功能性的异源蛋白质。相结合，这些协议将允许产生和能够提供异源的治疗性蛋白的胃肠道的益生菌酵母株的测试。

<table><tbody><tr><td>SmartSpec 3000 Spectrophotometer</td><td>BioRad</td><td>170-2501</td><td>Example of spectrophotometer for determining cell concentration and OD&lt;sub&gt;600&lt;/sub&gt; of yeast cultures</td></tr><tr><td>New Brunswick Roller Drum</td><td>Eppendorf</td><td>M1053-4004</td><td>Example of roller drum for yeast culture incubation</td></tr><tr><td>UV Stratalinker 2400</td><td>Stratagene</td><td>400075-03</td><td>Example stratalinker</td></tr><tr><td>Stuart Colony Counter SC6PLUS</td><td>11983044</td><td>Fisher Scientific</td><td>Plate stand with magnification records colony count upon sensing pressure from pen</td></tr><tr><td>Scienceware Colony Counter&amp;nbsp;</td><td>F378620002</td><td>Bel-Art Scienceware</td><td>Hand held colony counter pen</td></tr><tr><td>Replica plating device</td><td>Fisherbrand</td><td>09-718-1</td><td>Example of replica plating stand and pads&amp;nbsp;</td></tr><tr><td>Velveteen squares</td><td>Fisherbrand</td><td>09-718-2</td><td></td></tr><tr><td>L shaped sterile cell spreaders&amp;nbsp;</td><td>Fisherbrand</td><td>14665230</td><td></td></tr><tr><td>Deoxyribonucleic acid, single stranded from salmon testes</td><td>Sigma-Aldrich</td><td>D7656-1ML</td><td>Example carrier DNA for yeast LiOAc transformation</td></tr><tr><td>Gavage needles</td><td>Braintree Scientific</td><td>N-PK&amp;nbsp;002</td><td>For mice 15-20 g, the suggested needle is a 22 gauge (1.25 mm ball), 1 in long, straight reusable gavage needle. For mice weighing greater than 20&amp;nbsp;g, 20 gauge or larger straight or curved gavage needles may be used</td></tr><tr><td>1 ml sterile slip-tip disposable tuberculin syringe</td><td>Becton Dickinson</td><td>BD 309659</td><td></td></tr><tr><td>Blunt forceps such as Electron Microscopy Sciences 7&quot; (178 mm) serrated tip, broad grip forceps</td><td>Electron Microscopy Sciences</td><td>77937-28</td><td>Example of blunt forceps needed for dissection&amp;nbsp;</td></tr><tr><td>Straight and curved dissection scissors</td><td>Electron Microscopy Sciences</td><td>72966-02 and 72966-03</td><td>Examples of scissors needed for dissection</td></tr><tr><td>IMDM</td><td>Life technologies</td><td>12440053</td><td></td></tr></tbody></table>

transformation of probiotic yeast and their recovery from gastrointestinal immune tissues following oral gavage in mice

Development of recombinant oral therapy would allow for more direct targeting of the mucosal immune system and improve the ability to combat gastrointestinal disorders. Adapting probiotic yeast in particular for this approach carries several advantages. These strains have not only the potential to synthesize a wide variety of complex heterologous proteins but are also capable of surviving and protecting those proteins during transit through the intestine. Critically, however, this approach requires expertise in many diverse laboratory techniques not typically used in tandem. Furthermore, although individual protocols for yeast transformation are well characterized for commonly used laboratory strains, emphasis is placed here on alternative approaches and the importance of optimizing transformation for less well characterized probiotic strains. Detailing these methods will help facilitate discussion as to the best approaches for testing probiotic yeast as oral drug delivery vehicles and indeed serve to advance the development of this novel strategy for gastrointestinal therapy.

以下UV照射一个存活曲线的产生需要稀释的酵母细胞，使得不同的集落形成单位（CFU）能够形成的镀覆。收集上述各500μl的样品含有约5×10 6个细胞;然而，每板大于100个菌落都难以准确区分。电镀未稀释样品以及照射细胞的连续1点10稀释从而确保了CFU可以在每个UV剂量可以列举， 如在图1表明该CFU计数，乘以稀释因子，然后通过的总数量除以原始照射细?...

Watch this Scientific Journal Video about Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice at JoVE.com

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

这里介绍的是，可以用于开发，变换，管理，和测试益生菌酵母布拉酵母菌中异源蛋白质表达技术的统一描述。

益生菌酵母的转型及其胃肠道粘膜免疫组织恢复继小鼠口服灌胃

Development of recombinant oral therapy would allow for more direct targeting of the mucosal immune system and improve the ability to combat ...

transformation-probiotic-yeast-their-recovery-from-gastrointestinal

Universidad de Cartagena UDEC

Research

JoVE Journal

Immunology and Infection

12.4K 次观看.  Emory University School of Medicine. 这里介绍的是，可以用于开发，变换，管理，和测试益生菌酵母布拉酵母菌中异源蛋白质表达技术的统一描述。 

视频: Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production

Yarrowia lipolytica is a non-pathogenic, dimorphic and strictly aerobic yeast species. Owing to its distinctive physiological features and metabolic characteristics, this unconventional yeast is not only a good model for the study of the fundamental nature of fungal differentiation but is also a promising microbial platform for biochemical production and various biotechnological applications, which require extensive genetic manipulations. However, genetic manipulations of Y. lipolytica have been limited due to the lack of an efficient and stable genetic transformation system as well as very high rates of non-homologous recombination that can be mainly attributed to the KU70 gene. Here, we report an easy and rapid protocol for the efficient genetic transformation and for gene deletion in Y. lipolytica Po1g. First, a protocol for the efficient transformation of exogenous DNA into Y. lipolytica Po1g was established. Second, to achieve the enhanced double-crossover homologous recombination rate for further deletion of target genes, the KU70 gene was deleted by transforming a disruption cassette carrying 1 kb homology arms. Third, to demonstrate the enhanced gene deletion efficiency after deletion of the KU70 gene, we individually deleted 11 target genes encoding alcohol dehydrogenase and alcohol oxidase using the same procedures on the KU70 knockout platform strain. It was observed that the rate of precise homologous recombination increased substantially from less than 0.5% for deletion of the KU70 gene in Po1g to 33%-71% for the single gene deletion of the 11 target genes in Po1g KU70&#916;. A replicative plasmid carrying the hygromycin B resistance marker and the Cre/LoxP system was constructed, and the selection marker gene in the yeast knockout strains was eventually removed by expression of Cre recombinase to facilitate multiple rounds of targeted genetic manipulations. The resulting single-gene deletion mutants have potential applications in biofuel and biochemical production.

We herein report methods on the molecular genetic manipulation of the Yarrowia lipolytica Po1g strain for improved gene deletion efficiency. The resulting engineered Y. lipolytica strains have potential applications in biofuel and biochemical production.

可再生生物燃料及生化生产的非常规酵母基因工程

Yarrowia lipolytica is a non-pathogenic, dimorphic and strictly aerobic yeast species. Owing to its distinctive physiological features and metabolic ...

科研

遗传学

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System

Humanized mice (hu-mice) that feature a functional human immune system have fundamentally changed the study of human pathogens and disease. They can be used to model diseases that are otherwise difficult or impossible to study in humans or other animal models. The gut microbiome can have a profound impact on human health and disease. However, the murine gut microbiome is very different than the one found in humans. &#160;There is a need for improved pre-clinical hu-mice models that have an engrafted human gut microbiome. Therefore, we created double hu-mice that feature both a human immune system and stable human-like gut microbiome. NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice are one of the best animals for humanization due to their high level of immunodeficiency. However, germ-free NSG mice, and various other important germ-free mice models are not currently commercially available. Further, many research settings do not have access to gnotobiotic facilities, and working under gnotobiotic conditions can often be expensive and time consuming. Importantly, germ-free mice have several immune deficiencies that exist even after the engraftment of microbes. Therefore, we developed a protocol that does not require germ-free animals or gnotobiotic facilities. To generate double hu-mice, NSG mice were treated with radiation prior to surgery to create bone-marrow, liver, thymus-humanized (hu-BLT) mice. The mice were then treated with broad spectrum antibiotics to deplete the pre-existing murine gut microbiome. After antibiotic treatment, the mice were given fecal transplants with healthy human donor samples via oral gavage. Double hu-BLT mice had unique 16S rRNA gene profiles based on the individual human donor sample that was transplanted. Importantly, the transplanted human-like microbiome was stable in the double hu-BLT mice for the duration of the study up to 14.5 weeks post-transplant.

We describe a novel method for generating double humanized BLT-mice that feature a functional human immune system and a stable engrafted human-like gut microbiome. This protocol can be followed without the need for germ-free mice or gnotobiotic facilities.

具有稳定的人类状古特微生物群落和人类免疫系统的双人性化BLT小鼠模型

Humanized mice (hu-mice) that feature a functional human immune system have fundamentally changed the study of human pathogens and disease. They can be ...

生物化学

Probiotic Studies in Neonatal Mice Using Gavage

Adult mouse models have been widely used to understand the mechanism behind disease progression in humans. The applicability of studies done in adult mouse models to neonatal diseases is limited. To better understand disease progression, host responses and long-term impact of interventions in neonates, a neonatal mouse model likely is a better fit. The sparse use of neonatal mouse models can in part be attributed to the technical difficulties of working with these small animals. A neonatal mouse model was developed to determine the effects of probiotic administration in early life and to specifically assess the ability to establish colonization in the newborn mouse intestinal tract. Specifically, to assess probiotic colonization in the neonatal mouse, Lactobacillus plantarum (LP) was delivered directly into the neonatal mouse gastrointestinal tract. To this end, LP was administered to mice by feeding through intra-esophageal (IE) gavage. A highly reproducible method was developed to standardize the process of IE gavage that allows an accurate administration of probiotic dosages while minimizing trauma, an aspect particularly important given the fragility of newborn mice. Limitations of this process include possibilities of esophageal irritation or damage and aspiration if gavaged incorrectly. This approach represents an improvement on current practices because IE gavage into the distal esophagus reduces the chances of aspiration. Following gavage, the colonization profile of the probiotic was traced using quantitative polymerase chain reaction (qPCR) of the extracted intestinal DNA with LP specific primers. Different litter settings and cage management techniques were used to assess the potential for colonization-spread. The protocol details the intricacies of IE neonatal mouse gavage and subsequent colonization quantification with LP.

This study details the process of gavaging precise amounts of probiotics to neonatal mice. The experimental set-up was optimized to include but is not limited to probiotic dosing, methods of administration, and quantification of bacteria in the intestines.

新生儿小鼠益生菌的研究

Adult mouse models have been widely used to understand the mechanism behind disease progression in humans. The applicability of studies done in adult ...

免疫与感染

An Intestinal Gut Organ Culture System for Analyzing Host-Microbiota Interactions

The structure of the gut tissue facilitates close and mutualistic interactions between the host and the gut microbiota. These cross-talks are crucial for maintaining local and systemic homeostasis; changes to gut microbiota composition (dysbiosis) associate with a wide array of human diseases. Methods for dissecting host-microbiota interactions encompass an inherent tradeoff among preservation of physiological tissue structure (when using in vivo animal models) and the level of control over the experiment factors (as in simple in vitro cell culture systems). To address this tradeoff, Yissachar et al. recently developed an intestinal organ culture system. The system preserves a naive colon tissue construction and cellular mechanisms and it also permits tight experimental control, facilitating experimentations that cannot be readily performed in vivo. It is optimal for dissecting short-term responses of various gut components (such as epithelial, immunological and neuronal elements) to luminal perturbations (including anaerobic or aerobic microbes, whole microbiota samples from mice or humans, drugs and metabolites). Here, we present a detailed description of an optimized protocol for organ culture of multiple gut fragments using a custom-made gut culture device. Host responses to luminal perturbations can be visualized by immunofluorescence staining of tissue sections or whole-mount tissue fragments, fluorescence in-situ hybridization (FISH), or time-lapse imaging. This system supports a wide array of readouts, including next-generation sequencing, flow cytometry, and various cellular and biochemical assays. Overall, this three-dimensional organ culture system supports the culture of large, intact intestinal tissues and has broad applications for high-resolution analysis and visualization of host-microbiota interactions in the local gut environment.

This article presents a unique method for analyzing host-microbiome interactions using a novel gut organ culture system for ex vivo experiments.

分析宿主-微生物群相互作用的肠道肠道器官培养系统

The structure of the gut tissue facilitates close and mutualistic interactions between the host and the gut microbiota. These cross-talks are crucial for ...

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

With the development of microecology in recent years, the relationship between intestinal bacteria and inflammatory bowel disease (IBD) has attracted considerable attention. Accumulating evidence suggests that dysbiotic microbiota plays an active role in triggering or worsening the inflammatory process in IBD and that fecal microbiota transplantation (FMT) is an attractive therapeutic strategy since transferring a healthy microbiota to IBD patient could restore the appropriate host-microbiota communication. However, the molecular mechanisms are unclear, and the efficacy of FMT has not been very well established. Thus, further studies in animal models of IBD are necessary. In this method, we applied FMT from wild-type C57BL/6J mice to IL-10 deficient mice, a widely used mouse model of colitis. The study elaborates on collecting fecal pellets from the donor mice, making the fecal solution/suspension, administering the fecal solution, and monitoring the disease. We found that FMT significantly mitigated the cardiac impairment in IL-10 knockout mice, underlining its therapeutic potential for IBD management.

The interaction of genetic susceptibility, mucosal immunity, and intestinal microecological environment is involved in the pathogenesis of inflammatory bowel disease (IBD). In this study, we applied fecal microbiota transplantation to IL-10 deficient mice and investigated its impact on colonic inflammation and heart function.

白细胞介素10缺陷小鼠模型中粪便微生物群移植的治疗评估

With the development of microecology in recent years, the relationship between intestinal bacteria and inflammatory bowel disease (IBD) has attracted ...

Murine Fecal Isolation and Microbiota Transplantation

Gut microbiota dysbiosis plays a role in the pathophysiology of cardiovascular and metabolic disorders, but the mechanisms are not well understood. Fecal microbiota transplantation (FMT) is a valuable approach to delineating a direct role of the total microbiota or isolated species in disease pathophysiology. It is a safe treatment option for patients with recurrent Clostridium difficile infection. Preclinical studies demonstrate that manipulating the gut microbiota is a useful tool to study the mechanistic link between dysbiosis and disease. Fecal microbiota transplantation may help elucidate novel gut microbiota-targeted therapeutics for the management and treatment of cardiometabolic disease. Despite a high success rate in rodents, there remains translational changes associated with the transplantation. The goal here is to provide guidance in studying the effects of gut microbiome in experimental cardiovascular disease. In this study, a detailed protocol for the collection, handling, processing, and transplantation of fecal microbiota in murine studies is described. The collection and processing steps are described for both human and rodent donors. Lastly, we describe using a combination of the Swiss-rolling and immunostaining techniques to assess gut-specific morphology and integrity changes in cardiovascular disease and related gut microbiota mechanisms.

The goal here is to outline a protocol to investigate the mechanisms of dysbiosis in cardiovascular disease. This paper discusses how to aseptically collect and transplant murine fecal samples, isolate intestines, and use the "Swiss-roll" method, followed by immunostaining techniques to interrogate changes in the gastrointestinal tract.

小鼠粪便分离和微生物群移植

Gut microbiota dysbiosis plays a role in the pathophysiology of cardiovascular and metabolic disorders, but the mechanisms are not well understood. Fecal ...

Preparation and Maintenance of Bioexclusion IsoPositive Cage Experiment for Human Fecal Transplantation into Germ-Free Mice

Germ-free mice are an important investigation tool for understanding the contribution of microorganisms in host health and disease, enabling assessment of the specific role of individuals, defined or complex groups of microorganisms in host response. Traditionally bred and reared in flexible-film or semi-rigid isolators, germ-free mouse husbandry and experimental manipulation are costly and require numerous trained staff and a large space footprint in animal housing facilities. The IsoPositive caging system allows for experimental manipulation of germ-free mice in individual, hermetically-sealed, positive-pressure isolator cages (isocages), reducing cost and enabling greater flexibility in experimental manipulations. 
Here, a protocol is described for transferring germ-free mice from breeding isolators to isocages and subsequent fecal transfer from human donor stool into mice to create stable long-term gut "humanized" mice for future studies. The materials and preparation needed for the utilization of the isocage system are described, including the use of chlorine-dioxide sterilant chemical sterilant to clean cages, supplies, equipment, and personal protective equipment. The methods for confirming the germ-free status of transferred mice and how to determine contamination in the caging system are discussed. The procedure for husbandry, including bedding, food, and water supply, is further discussed. The protocol for human fecal slurry preparation and gavage into germ-free mice to create gut "humanized" mice, along with stool collection to monitor the microbial community composition of these mice, are described. An experiment illustrates that two weeks post-human fecal transplant allows for stable colonization of donor microbiota in the murine hosts, enabling subsequent experimental usage. Furthermore, the collection of humanized mouse feces in viability preservation media, enabling use in further functional experiments, is described. Overall, these methods allow for the safe and effective establishment of humanized mouse communities in experimental gnotobiotic cages for further manipulation.

This protocol describes the best practices for germ-free mouse transfer to and housing in experimental single-cage isolators (isocages) while maintaining sterile conditions. Methods for fecal transplant into germ-free mice and the collection of viable bacteria from these gut "humanized" mice for further applications are discussed.

用于人粪便移植到无菌小鼠体内的生物排斥 IsoPositive 笼实验的制备和维持

Germ-free mice are an important investigation tool for understanding the contribution of microorganisms in host health and disease, enabling assessment of ...

Fecal Microbiota Transplantation and Detection of Prevalence of IgA-Coated Bacteria in the Gut

Gut microbiota exert pleiotropic roles in human health and disease. Fecal microbiota transplantation (FMT) is an effective method to investigate the biological function of intestinal bacteria as a whole or at the species level. Several different FMT methods have been published. Here, we present an FMT protocol that successfully depletes gut microbiota in a matter of days, followed by transplantation of fecal microbiota from fresh or frozen donor intestinal contents to conventional mice. Real time-PCR is applied to test the efficacy of bacterial depletion. Sequencing of the 16S ribosomal RNA (rRNA) is then applied to test the relative abundance and identity of gut microbiota in recipient mice. We also present a flow cytometry-based detection method of immunoglobulin A (IgA)-coated bacteria in the gut.

<meta charset="utf8"></head><body>粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

We established an efficient way to deplete intestinal bacteria in three days, and subsequently transplant fecal microbiota via gavage of fecal fluid prepared from fresh or frozen intestinal contents in mice. We also present an optimized method to detect the frequency of IgA-coated bacteria in the gut.

粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

Gut microbiota exert pleiotropic roles in human health and disease. Fecal microbiota transplantation (FMT) is an effective method to investigate the ...

生物学

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Gut microbiota dysbiosis is thought to exert a role in the progression of colitis. However, the precise standards for probiotic administration in alleviating colitis remain undefined. Most analysis methods rely on limited diversity and abundance of gut microorganisms. Therefore, observational studies cannot establish causation. In this study, we applied antibiotic-induced pseudo-germ-free mice to investigate the role of gut microbiota in regulating the probiotic effects of Bacillus&#160;cereus (B. cereus)&#160;on dextran sulfate sodium (DSS)-induced colitis in mice. This process allows for evaluating the bidirectional regulating effect of B. cereus&#160;supplementation on health and provides stable and reproducible results. Here, the detailed protocols for B. cereus cultivation, gavage operation, stool collection, and antibiotic clearance treatment on colitis mice are provided. The optimization methods are also applicable for other chronic inflammatory-associated disorders. The results showed that B. cereus administration decreased body weight loss, colon length shortening, disease activity index, and histopathological scores. However, treatment with antibiotics suppressed the positive effect of B. cereus on colitis. These results indicate that gut microbiota are needed for the alleviating effects of B. cereus on colitis. Therefore, exploring the beneficial effects of probiotics in this research is a promising approach for developing novel treatment strategies for alleviating the symptoms of chronic inflammatory-associated disorders.

<meta charset="utf8"></head><body>研究蜡样芽孢杆菌给药通过肠道微生物群调节对结肠炎的缓解作用

Here, we present a protocol to establish the antibiotic-induced pseudo-germ-free dextran sulfate sodium-induced colitis mouse model to investigate the role of gut microbiota in regulating the positive effects of Bacillus cereus on colitis.

益生菌酵母的转型及其胃肠道粘膜免疫组织恢复继小鼠口服灌胃

摘要

探索更多视频

可再生生物燃料及生化生产的非常规酵母基因工程

具有稳定的人类状古特微生物群落和人类免疫系统的双人性化BLT小鼠模型

新生儿小鼠益生菌的研究

分析宿主-微生物群相互作用的肠道肠道器官培养系统

白细胞介素10缺陷小鼠模型中粪便微生物群移植的治疗评估

小鼠粪便分离和微生物群移植

用于人粪便移植到无菌小鼠体内的生物排斥 IsoPositive 笼实验的制备和维持

粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

研究蜡样芽孢杆菌给药通过肠道微生物群调节对结肠炎的缓解作用

益生菌酵母的转型及其胃肠道粘膜免疫组织恢复继小鼠口服灌胃

摘要

探索更多视频

可再生生物燃料及生化生产的非常规酵母基因工程

具有稳定的人类状古特微生物群落和人类免疫系统的双人性化BLT小鼠模型

新生儿小鼠益生菌的研究

分析宿主-微生物群相互作用的肠道肠道器官培养系统

白细胞介素10缺陷小鼠模型中粪便微生物群移植的治疗评估

小鼠粪便分离和微生物群移植

用于人粪便移植到无菌小鼠体内的生物排斥 IsoPositive 笼实验的制备和维持

粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

粪便微生物群移植和肠道中 IgA 包被细菌患病率的检测

研究蜡 样芽孢杆菌 给药通过肠道微生物群调节对结肠炎的缓解作用

研究蜡样芽孢杆菌给药通过肠道微生物群调节对结肠炎的缓解作用